GlassScriptPhysician profile
Afsaneh Barzi
NPI 1265480412
$107,355.16
in general payments reported to CMS, 2019-2025
15 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,971 · 2020: $19.68 · 2021: $29K · 2022: $14K · 2023: $40K · 2024: $19K · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Travel and Lodging: $12K · Food and Beverage: $890 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,753.25 |
| Travel and Lodging | $12,117.03 |
| Food and Beverage | $890.34 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43,573.10 | 2019-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $21,071.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $16,694.89 | 2021-2024 | Enhertu, Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $11,714.92 | 2023-2024 | Fruzaqla |
| Daiichi Sankyo INC. | $6,233.75 | 2021-2024 | |
| Amgen INC. | $2,758.25 | 2023 | Lumakras |
| Astellas Pharma US INC | $2,402.73 | 2023 | |
| Seagen INC. | $1,375.00 | 2022 | |
| Astrazeneca Uk Limited | $875.00 | 2019 | |
| Beigene USA, INC. | $222.76 | 2024 | |
| Merck Sharp & Dohme LLC | $187.96 | 2019-2020 | |
| Beone Medicines USA, INC. | $156.98 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.96 | 2024 | Opdivo |
| Dentsply Sirona INC | $13.98 | 2024 | Suresmile |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afsaneh Barzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.